ArticleTranslational cancer research2020
Effects of knockout of long-chain non-coding RNA LSINCT5 on proliferation, apoptosis, epithelial-mesenchymal transition, and p38MAPK pathway of pancreatic cancer PANC-1 cells.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Spheroids and organoids to study long noncoding RNAs in cancer: how they could replace animal models.Cancer metastasis reviews · 2026Review
- LSINCT5: a pivotal oncogenic long non-coding RNA in cancers.Functional & integrative genomics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur study aims to investigate the effects of the knockout of long non-coding RNA LSINCT5 (lncRNA LSINCT5) on the proliferation, apoptosis, epithelial-mesenchymal transition (EMT), and p38MAPK pathway of pancreatic cancer PANC-1 cells, to provide a basis for searching for the therapeutic targets of pancreatic cancer.
methodsThe laboratory findings and clinical data of 21 patients with pancreatic cancer were retrospectively collected, and the survival rates of patients with high or low lncRNA LSINCT5 expressions were analyzed. PANC-1 cells were randomly divided into the control group, shRNA-NC group, and sh-LSINCT5 group, and the constructed sh-LSINCT5 and shRNA-NC vectors were transfected into the corresponding cells. The successful interference of lncRNA LSINCT5 was confirmed by reverse transcription polymerase chain reaction (RT-PCR). CCK-8 and spherogenesis assay detected the proliferation and spherogenesis of PANC-1 cells. The apoptosis rate was evaluated by flow cytometry. Western blotting was used to identify the expressions of KI67, PCNA, SOX2, OCT4, E-cadherin, N-cadherin, and Vimentin and the activation of Caspase-3 and Caspase-9.
resultsThe survival rate of patients with low lncRNA LSINCT5 expression was higher than that of patients with high lncRNA LSINCT5 expression. Compared with the control group, lncRNA LSINCT5 knockout significantly down-regulated the expressions of KI67, PCNA, SOX2, OCT4, cleaved Caspase-3, cleaved Caspase-9, N-cadherin and Vimentin (all P<0.05) and significantly decreased the cell proliferation, sphere size, and number of spheres in PANC-1 cells (all P<0.05); meanwhile, it up-regulated the protein expression of E-cadherin (P<0.05), along with the significantly increased number of apoptotic PANC-1 cells (P<0.05). In addition, compared with the control group, the level of p38 phosphorylation significantly dropped after lncRNA LSINCT5 knockout (P<0.05).
conclusionsKnockout of lncRNA LSINCT5 can inhibit the proliferation, EMT, and p38MAPK pathway of PANC-1 cells and meanwhile promote the apoptosis of PANC-1 cells. Therefore, lncRNA LSINCT5 may be a promising therapeutic target for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.